Repligen Corporation (RGEN)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $10.73B
Last updated: Nov 17, 2026 at 11:06 AM ET
Repligen Corporation (RGEN) Stock Forecast
Analysts expect Repligen (RGEN) to earn $2.07 per share in the fiscal year ending Dec 31, 2026, on revenue of $848.82M. Of 20 analysts, 16 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 8 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 20 ratings average 2.05, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 15.0% |
| Buy | 13 | 65.0% |
| Hold | 4 | 20.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 20
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 28.0% and revenue estimates rise 26.1%.
- Fiscal year ending Dec 31, 2026
- $2.07
- EPS consensus, revenue $848.82M
- Fiscal year ending Dec 31, 2027
- $2.65
- EPS consensus, revenue $1.07B
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.07 | $2.05 to $2.09 | 20 | $848.82M | $845.54M to $853.40M | 20 |
| Dec 31, 2027 | $2.65 | $2.47 to $2.92 | 19 | $1.07B | $1.05B to $1.10B | 19 |
Quarterly Estimates
The EPS consensus rises from $0.53 for the quarter ending Dec 31, 2026 to $0.60 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.53 | $0.49 to $0.57 | 19 | $244.68M | $215.01M to $257.99M | 20 |
| Mar 31, 2027 | $0.60 | $0.53 to $0.67 | 10 | $250.28M | $245.60M to $252.70M | 10 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 20 upward and 12 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 8 | 5 |
| Fiscal year ending Dec 31, 2027 | 8 | 4 |
| Quarter ending Mar 31, 2027 | 4 | 3 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 is where it was 90 days ago.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.07 | $2.07 | $2.06 | $2.07 | $2.07 | +0.4% |
| Fiscal year ending Dec 31, 2027 | $2.65 | $2.65 | $2.63 | $2.63 | $2.64 | +0.6% |
| Quarter ending Mar 31, 2027 | $0.60 | $0.59 | $0.59 | $0.59 | $0.59 | +0.9% |
Frequently Asked Questions About RGEN
What is the RGEN stock forecast?
Consensus analyst estimates put Repligen's EPS at $2.07 for the fiscal year ending Dec 31, 2026, on revenue of $848.82M. The consensus rating from 20 analysts is Buy.
How do analysts rate RGEN stock?
Of 20 analysts covering Repligen, 3 rate it Strong Buy, 13 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RGEN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.07, with estimates from $2.05 to $2.09 from 20 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.65, with estimates from $2.47 to $2.92 from 19 analysts.
What revenue do analysts expect from Repligen next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $848.82M, with estimates from $845.54M to $853.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.07B, with estimates from $1.05B to $1.10B.
How many analysts cover RGEN?
20 analysts rate Repligen stock, and 20 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts